July 22, 2021
REZUROCKTM (belumosudil) tablets approved to treat adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of therapy
June 4, 2021
LUMAKRAS (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
June 1, 2021
ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
March 15, 2021
Onco360® Selected as Specialty Pharmacy Partner for FOTIVDA® (tivozanib)
February 8, 2021
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
December 17, 2020
Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.
June 22, 2020
TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.
May 13, 2020
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
April 20, 2020
Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
April 13, 2020
Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.